



The Extraordinary Shareholders' Meeting of Neurosoft S.A. today approved:

- a free share capital increase of 6.65 mln/€
- granting authorization to the BoD for a common debenture loan up to 15 mln/€

The Extraordinary Shareholders' Meeting of Neurosoft S.A. – a company under Greek law listed in AIM Italia market (ISIN [GRS802003004](#), [Reuters NRST.MI](#), [Bloomberg NRST:IM](#)) for which Banca Akros is Nominated Adviser - today approved a share capital increase of euro 6,650,000 (six million six hundred and fifty thousand), by use of part of the share premium reserve with ensuing proportional allocation to shareholders of 19 free shares at par value 0.35 euros each for every 6 shares held (namely 19,000,000 new shares in total) and with the corresponding amendments to article 5 of the articles of association.

The goal of this operation is twofold: to reward current shareholders within the framework of the fidelization strategy and to enhance the liquidity of NEUROSOFT's shares, through the reduction of the amount of investment required per share, thus helping Company's stock to be more attractive to a broader range of investors and expand the shareholder base.

Moreover, the Extraordinary Shareholders' Meeting granted authorization to the Board of Directors to negotiate, issue and take out a non convertible common debenture loan up to euro 15,000,000 (fifteen million) with MILLENNIUM BANK S.A. or other bank as may be decided by the Board of Directors. The loan, of a 7 year term, shall bear floating interest rate at 6 months EURIBOR plus a spread of up to 3.75% p.a. and shall be amortized in 14 semi annual instalments.

These funds shall be used to acquire the 3 high-technology companies of Fasbet Group - namely Wray & Entwisle, Fasbet UK Ltd, Fasbet IOM Ltd (an acquisition still subject to due diligence, amounting to euro 2.450.000)- and to further develop technology and know-how aiming to provide integrated top quality services through the creation of a large and robust technological group with more flexibility taking advantage of rapid developments in technology and in the high-tech market.

Neurosoft S.A., a company under Greek law quoted in AIM Italia (ISIN [GRS802003004](#), [Reuters NRST.MI](#), [Bloomberg NRST:IM](#)), is specialized in the design, development, customization and maintenance of **software solutions developed in-house** for the sectors of sports betting, factoring and business intelligence.

Banca Akros is Neurosoft's Nominated Adviser for the AIM Italia market. Neurosoft was founded in 1994 and today is considered the **Premier Hellenic Software House**, specializing in the areas of Business Intelligence, Risk & Liability Management, Business Process Management, Middleware Transactional System, Core Factoring and the implementation of Mission Critical custom application. Neurosoft develops internally products thanks to a team of highly specialized professionals that they constitute the asset carrying of the technology and the excellence of the Company. Neurosoft, in fact, constantly careful to the new technologies in computer science field and the field of software, invests meaningful financial resources in Research & Development: in 2006 approximately 2.7%, in 2007 approximately 3.2%, in 2008 the 4.1% of its turnover with the aim of offering its customers innovative solutions that represent the "state of the art" to an international level.

Neurosoft offers services and technological solutions in Greece and numerous international markets, in continuous expansion, also thanks to strategic alliances with operating heads in the field of the technologies in support of the Sport, Gaming & Betting. In 2008 the Company has opened a branch (office) to Bucharest - Neurosoft Rumania SRL - with the objective to expand its presence in the East Europe and to service at best the needs and requirements of its customers.

Today Neurosoft is a Software house consolidated with a pocketbook of projects and global partners who, in spite of the difficulty of the international economic context, is experiencing an increase without precedent.

In 2008 Neurosoft has recorded, in fact, a turnover equal to €3,7 million (greater than a 100% increase relatively to 2007), an EBITDA equal to €2,1 million (greater than a fivefold increase over 2008), a net profit equal to €1,5 million (greater than a six fold increase).

On behalf of Neurosoft SA

Weber Shandwick | Advisory

Giorgio Catalano 0039 3346969275
gcatalano@advisorywebershandwick.it

Carmelinda Carcione 0039 3356111390
ccarcione@advisorywebershandwick.it